DDInter904 DDInter927
An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Idarubicin {u} (Compound) resembles {v} (Compound) Valrubicin
Idarubicin {u} (Compound) treats {v} (Disease) breast cancer
Idarubicin {u} (Compound) binds {v} (Gene) CYP2C9
Idarubicin {u} (Compound) upregulates {v} (Gene) MEGF8
Idarubicin {u} (Compound) is included by {v} (Pharmacologic Class) Topoisomerase Inhibitors
Idarubicin {u} (Compound) downregulates {v} (Gene) CBR3
Idarubicin {u} (Compound) causes {v} (Side Effect) Haemorrhage
Idarubicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cinoxacin
Idarubicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Delafloxacin
Idarubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Triclabendazole
Idarubicin (Compound) resembles Valrubicin (Compound)
Idarubicin (Compound) treats breast cancer (Disease)
Idarubicin (Compound) binds CYP2C9 (Gene)
Idarubicin (Compound) upregulates MEGF8 (Gene)
Idarubicin (Compound) is included by Topoisomerase Inhibitors (Pharmacologic Class)
Idarubicin (Compound) downregulates CBR3 (Gene)
Idarubicin (Compound) causes Haemorrhage (Side Effect)
Idarubicin may cause a minor interaction that can limit clinical effects when taken with Cinoxacin
Idarubicin may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole